ADG106
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for ADG106, covering 2022-03-25 to 2025-07-25. Get the full timeline:
Most recent: Clinical Trial Update: A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer [Phase 1, Phase 2]